Drug Profile
Tilsotolimod - Aceragen
Alternative Names: IMO-2125; IMO-2125 sodium; Tilsotolimod sodiumLatest Information Update: 27 Apr 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer AbbVie; Aceragen; Bristol-Myers Squibb
- Class Antineoplastics; Antivirals; Immunotherapies; Oligodeoxyribonucleotides
- Mechanism of Action Immunologic cytotoxicity; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Colorectal cancer; Head and neck cancer; Hepatitis C; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 13 Apr 2023 Tilsotolimod is available for licensing as of 01 Dec 2021. https://www.aceragen.com/
- 28 Feb 2023 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in France (Intratumoural, Injection)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in Germany (Intratumoural, Injection)